Financial support options may be available for SAPHNELO
Resources to help patients along the SAPHNELO treatment journey.
SAPHNELO Co-pay Savings Program
The SAPHNELO Co-pay Savings Program helps assist eligible, commercially insured patients with out-of-pocket costs.
AZ&Me Prescription Savings Program provides AstraZeneca medicines at no cost to qualifying patients.
Independent Patient Assistance Foundations
Assistance may be available through independent foundations such as those listed below. Foundations can provide a variety of assistance types: patient savings, transportation, premium, patient education, etc.
What to know
SAPHNELO Supports Has Information Your Patient May Need—In One Place
SAPHNELO Supports is a patient support program created to help answer the questions your patient might have as they get started with their treatment. Access 360 is a part of SAPHNELO Supports and can help you find information about coverage, costs, and affordability programs.
We can answer their questions about:
- Insurance coverage
- Out-of-pocket costs
- Making their medicine more affordable
Have your patient contact SAPHNELO Supports to learn more, Monday to Friday, 8 AM to 6 PM ET, excluding holidays
One MedImmune Way, Gaithersburg, MD 20878Who can apply?
- Patients who are covered by commercial insurance and their insurance does not cover the full cost of their prescription
- Residents of the United States or Puerto Rico
- Patients are ineligible if prescriptions are paid by any State or Federally funded programs, including but not limited to, Medicare Part B, Medicare Part D, Medicaid, Medigap, Veterans Affairs, Department of Defense, or TRICARE
- Patients with a valid prescription to accompany the FASENRA Co-pay Savings Program offer
What to know
What happens once an eligible patient is enrolled in the SAPHNELO Co-pay Savings Program?
A Co-pay Savings Program account will be created for the eligible patient. This can be done by the pharmacy/practice or by calling an Access 360 representative. Once enrolled, the patient will continue to pay a set amount of his or her out-of-pocket costs for SAPHNELO. The pharmacy/practice will use the Co-pay Savings Program to cover the balance, up to the program maximum.
What are the specific costs associated with the SAPHNELO Co-pay Savings Program?
The patient may pay as little as $0 per administration; program pays remaining out-of-pocket costs up to a maximum of $16,500 per year. The out-of-pocket costs covered by the program can include the cost of the product itself and/or the cost of infusion of the product (program maximum of $150 per infusion administration). Patients who are residents of Massachusetts or Rhode Island are not eligible for infusion administration assistance.
What does the SAPHNELO Co-pay Savings Program cover?
The SAPHNELO Co-pay Savings Program covers the cost of the drug and administration but does not cover costs for office visits or any other associated costs.
Are there income requirements to participate in the program?
No. There are no income requirements to participate in the program.
Where can I find additional information?
For additional information, please visit http://www.saphnelosupport.com or call an Access 360 representative at 1-866-SAPHNELO (1-866-727-4635).
Eligibility & Terms of Use
The SAPHNELO® (anifrolumab-fnia) injection for Intravenous infusion, 300 mg Savings Program is for commercially insured patients to cover patient out-of-pocket costs for SAPHNELO and its infusion administration up to $16,500 per calendar year. Patients with commercial insurance where the health plan does NOT cover SAPHNELO may qualify for the Denied Co-pay Savings Program. Subject to eligibility and terms of use.
Patients must have commercial health insurance and a valid prescription for SAPHNELO. Patients who are enrolled in a state or federally funded prescription insurance program are not eligible for this offer. This includes patients enrolled in Medicare Part B, Medicare Part D, Medicaid, Medigap, Veterans Affairs (VA), Department of Defense (DoD) programs or TriCare, and patients who are Medicare eligible and enrolled in an employer-sponsored group waiver health plan or government-subsidized prescription drug benefit program for retirees. Patients who are enrolled in a state or federally funded prescription insurance program may not use this program even if they elect to be processed as an uninsured (cash-paying) patient. This offer is not insurance and is restricted to residents of the United States and Puerto Rico. Patients who are residents of Massachusetts or Rhode Island are not eligible for infusion administration assistance.
Other restrictions may apply. Patient must be enrolled in the program before use. See full Eligibility and Terms of Use at www.SAPHNELO.com or call Access 360 at 1-866-SAPHNELO (1-866-727-4635), Monday–Friday, 8 AM to 6 PM ET, excluding holidays.
A Co-pay Savings Program account will be created for the eligible patient. This can be done by the pharmacy/practice or by calling an Access 360 representative. Once enrolled, the patient will continue to pay a set amount of his or her out-of-pocket costs for SAPHNELO. The pharmacy/practice will use the Co-pay Savings Program to cover the balance, up to the program maximum.
The patient may pay as little as $0 per administration; program pays remaining out-of-pocket costs up to a maximum of $16,500 per year. The out-of-pocket costs covered by the program can include the cost of the product itself and/or the cost of infusion of the product (program maximum of $150 per infusion administration). Patients who are residents of Massachusetts or Rhode Island are not eligible for infusion administration assistance.
The SAPHNELO Co-pay Savings Program covers the cost of the drug and administration but does not cover costs for office visits or any other associated costs.
No. There are no income requirements to participate in the program.
For additional information, please visit http://www.saphnelosupport.com or call an Access 360 representative at 1-866-SAPHNELO (1-866-727-4635).
The SAPHNELO® (anifrolumab-fnia) injection for Intravenous infusion, 300 mg Savings Program is for commercially insured patients to cover patient out-of-pocket costs for SAPHNELO and its infusion administration up to $16,500 per calendar year. Patients with commercial insurance where the health plan does NOT cover SAPHNELO may qualify for the Denied Co-pay Savings Program. Subject to eligibility and terms of use.
Patients must have commercial health insurance and a valid prescription for SAPHNELO. Patients who are enrolled in a state or federally funded prescription insurance program are not eligible for this offer. This includes patients enrolled in Medicare Part B, Medicare Part D, Medicaid, Medigap, Veterans Affairs (VA), Department of Defense (DoD) programs or TriCare, and patients who are Medicare eligible and enrolled in an employer-sponsored group waiver health plan or government-subsidized prescription drug benefit program for retirees. Patients who are enrolled in a state or federally funded prescription insurance program may not use this program even if they elect to be processed as an uninsured (cash-paying) patient. This offer is not insurance and is restricted to residents of the United States and Puerto Rico. Patients who are residents of Massachusetts or Rhode Island are not eligible for infusion administration assistance.
Other restrictions may apply. Patient must be enrolled in the program before use. See full Eligibility and Terms of Use at www.SAPHNELO.com or call Access 360 at 1-866-SAPHNELO (1-866-727-4635), Monday–Friday, 8 AM to 6 PM ET, excluding holidays.
